At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 61 enrolled
Drug / intervention
AMG 479biological
Likely dose
AMG 479 18 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Open Label Phase II Study of the Efficacy and Safety of AMG 479, a Fully Human Monoclonal Antibody Against Insulin-like Growth Factor Type 1 Receptor (IGF-1R) as Second Line Therapy in Patients With Recurrent Platinum Sensitive Ovarian Cancer
In Brief
A Phase 2 clinical trial evaluating AMG 479 for Ovarian Neoplasms. Completed, enrolled 61 participants across 37 sites in 7 countries.
Detailed Summary
The purpose of this study is to obtain an estimate of the objective response rate (ORR) of AMG 479 in patients with recurrent platinum-sensitive ovarian epithelial (including fallopian tube and primary peritoneal) carcinoma failing frontline chemotherapy.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsOvarian Neoplasms
CountriesCanada, France, Germany, Ireland, Israel, Spain, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 2008
Enrollment StartJan 2009
Primary CompletionMay 2013
TodayJul 2026
First PostedJul 21, 2008
Enrollment StartJan 1, 2009
Primary CompletionMay 1, 2013
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 17.9 years ago
Interventions
AMG 479biological
Solution for infusion - 18 mg/kg on day 1 of each 21-day cycle